As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Structure Therapeutics Inc. The largest reported stake is Fmr LLC's, at 15%. 16 filings are on record since August 6, 2025 (Schedule 13G/A, November 5, 2026).
Who owns Structure Therapeutics Inc.?
Sell to companies like Structure Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 32,089,422 · Shared voting: 0 · Sole dispositive: 32,089,434 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Holder: Fmr LLC · Percent: 13.2% · SCHEDULE 13G/A
- · Holder: Bvf Partners L P · Percent: 4.9% · SCHEDULE 13G/A
- · Holder: Deep Track Capital, LP · Percent: 5.95% · SCHEDULE 13G/A
- · Holder: Wellington Management Group LLP · Percent: 10.1% · SCHEDULE 13G/A
Structure Therapeutics Inc has 16 Schedule 13D or 13G filings on record since 2025-08-06. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 32,089,434 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Wellington Management Group LLP | 10.1% | 21,365,952 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| Avoro Capital Advisors LLC | 9.38% | 16,216,665 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Janus Henderson Group Plc | 7.7% | 4,448,826 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Deep Track Capital, LP | 5.95% | 12,335,346 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Bvf Partners L P | 4.9% | 10,437,066 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Structure Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Structure Therapeutics Inc and the records around it.
Structure Therapeutics Inc elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Structure Therapeutics Inc
Get an email when Structure Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Structure Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Structure Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Structure Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 32,089,422 | 0 | 32,089,434 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 32,089,434 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Structure Therapeutics Inc by CUSIP 86366E106 and gives its principal executive office as 601 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Fmr LLC | 11.6% | SCHEDULE 13G/A |
| 2025-08-12 | Wellington Management Group LLP | 12% | SCHEDULE 13G/A |
| 2025-08-14 | Deep Track Capital, LP | 8.92% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 8% | SCHEDULE 13G/A |
| 2025-08-18 | Bvf Partners L P | 5.6% | SCHEDULE 13G |
| 2025-11-07 | Wellington Management Group LLP | 9.9% | SCHEDULE 13G/A |
| 2025-11-07 | Wellington Management Group LLP | 11.9% | SCHEDULE 13G/A |
| 2025-11-14 | Avoro Capital Advisors LLC | 9.38% | SCHEDULE 13G |
| 2025-11-14 | Deep Track Capital, LP | 7.32% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 7.7% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 10.1% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 5.95% | SCHEDULE 13G/A |
| 2026-02-17 | Bvf Partners L P | 4.9% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 13.2% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
Questions about who owns Structure Therapeutics Inc
Who owns Structure Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Structure Therapeutics Inc: Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05), Wellington Management Group LLP (10.1%, Schedule 13G/A, filed 2026-02-10), Avoro Capital Advisors LLC (9.38%, Schedule 13G, filed 2025-11-14), Janus Henderson Group Plc (7.7%, Schedule 13G/A, filed 2025-11-14) and Deep Track Capital, LP (5.95%, Schedule 13G/A, filed 2026-02-13).
Who are the largest shareholders of Structure Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Structure Therapeutics Inc on this page are Fmr LLC (15%), Wellington Management Group LLP (10.1%) and Avoro Capital Advisors LLC (9.38%).
When did Fmr LLC buy into Structure Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-08-06, reporting 11.6%; its latest, Schedule 13G/A filed 2026-11-05, reports 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Structure Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 15, 2026 | Leadership change: Matthew Lang appointed, Chief Operating Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Structure Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.